Wordt geladen...
Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
Recent studies suggest that JAK2 serves as a novel therapeutic target in Bcr-Abl+ chronic myelogenous leukemia (CML). We have reported the existence of an HSP90- associated high molecular weight network complex (HMWNC) that is composed of HSP90 client proteins BCR-ABL, JAK2, and STAT3 in wild type B...
Bewaard in:
| Gepubliceerd in: | Genes Cancer |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979592/ https://ncbi.nlm.nih.gov/pubmed/27551334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/genesandcancer.111 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|